Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion

NCT05903560 · tracked via the Priya Life Science China tracker

Sponsor

Jinling Hospital, China

Phase

Not applicable

Started

2023-07-22

Last updated

2026-04-30

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

endovascular recanalization via radial approachendovascular recanalization via femoral approach

endovascular recanalization via radial approach: Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via radial approach

endovascular recanalization via femoral approach: Patients with basilar artery occlusion within 24 hours of onset will be chosen to receive endovascular recanalization via femoral approach

Study summary

Stroke is one of the most important diseases endangering the health and quality of life of Chinese people. Acute ischemic stroke (AIS) is commonly caused by cerebrovascular stenosis or occlusion. The most effective treatment for AIS is timely and successful angiographic reperfusion.

Due to the large diameter and obvious positioning of bilateral femoral arteries, the transfemoral artery (TFA) using Seldinger's technique has been the most commonly used approach for endovascular treatment. However, recent studies have suggested that the radial artery is an ideal puncture site for cerebrovascular intervention. Small sample studies have confirmed that endovascular recanalization for acute anterior circulation large vessel occlusion via TRA has been safe and effective. Still, there are some complex approaches needed to be converted to TFA. There has been no difference in total operation duration and fluoroscopy time between TRA and TFA, but the TRA group had higher radiation dose and shorter hospital stays than the TFA group. In addition, TRA tends to be more convenient than TFA, especially for posterior circulation lesions.

However, the current studies are based on a single center with a small sample size, and there has been still a lack of large-sample randomized controlled experiments to verify the safety and effectiveness of posterior endovascular recanalization via TRA.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Acute ischemic stroke in the posterior circulation confirmed by symptoms and imaging examinations. 2. Basilar artery occlusion confirmed by computed tomographic angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA). 3. Age ≥ 18 years. 4. Time from symptom onset to randomization within 24 hours of the estimated time of basilar artery occlusion. 5. Baseline NIHSS score ≥ 10 before randomization. 6. Intact dual circulation of the hand assessed by the modified Allen's test. 7. Written informed consent from patients or their legally authorized representatives. Exclusion Criteria: 1. Pre-stroke disability with mRS score ≥ 3. 2. Pregnant or lactating women. 3. Allergic to contrast agents or nitinol devices. 4. Participation in other clinical trials. 5. Systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110mmHg, and can not be controlled by antihypertensive drugs. 6. Known genetic or acquired bleeding diathesis, lack of coagulation factors; or oral anticoagulant therapy with INR \> 1.7. 7. Baseline lab values: blood glucose \< 50mg/dL (2.8mmol/L) or \> 400mg/dL (22.2 mmol/L), platelet count \< 50\*109 /L, or hematocrit \< 25%. 8. Life expectancy less than 1 year. 9. Lost to follow-up within 90 days (e.g. no fixed residence, overseas patients, etc.). 10. Acute ischemic stroke within 48 hours after percutaneous coronary intervention, cerebrovascular intervention, or major surgery (patients can be included if more than 48 hours). 11. Clinical manifestations of central nervous system vasculitis. 12. Premorbid nervous system diseases or mental disorders hindering the assessment of the disease. 13. Diseases or anatomical abnormalities that make it difficult for radial or femoral artery puncture, sheath insertion or instrument delivery, such as local infection, anatomical abnormalities confirmed by ultrasound or other imaging examinations, previous interventional or open surgery.

Primary outcome measure(s)

The proportion of favorable neurological function at 90 days (defined as mRS score ≤ 3) — 90 days after randomization
mRS is short for modified Ranking score (ranging from 0 to 6, with higher values indicating a worse functional outcome)

Trial sites (1)

Facility	City	Region	Status
Department of Neurology, Jinling Hospital	Nanjing	Jiangsu	Recruiting

More Jinling Hospital, China trials in China

A Multi-modal Cohort Study of Brown Adipose Tissue Based on Paired Comparisons at Room Temperature and After Cold Exposure Recruiting

A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma Recruiting

Gastric Feeding for the Prevention of Stroke-Associated Pneumonia Starting soon

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy Recruiting

Dongzong Cardiovascular Bio-imaging Registry Study Recruiting

Other trials for the same condition

RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction Starting soon

Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Starting soon

Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS) Starting soon

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke Recruiting

Fructose for Acute Ischemic Stroke Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05903560 on ClinicalTrials.gov ↗ ← All trials in China